causes

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

LEHI, Utah, Oct. 23, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes…

1 week ago

realbuzz Raise over 12.6M Globally For Charity

Friday 4 July, 2025 Manchester-based global fundraising platform realbuzz has revealed a post covid record breaking year in its FY24/25…

4 months ago